logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Preventing Mycobacterium avium complex in patients who are using protease inhibitors : a cost-effectiveness analysis.

    Article - En anglais

    Background 

    Practice guidelines recommending Mycobacterium avium complex (MAC) prophylaxis for patients with HIV disease were based on clinical trials in which individuals did not receive protease inhibitors.

    Objective 

    To estimate the cost-effectiveness of strategies for MAC prophylaxis in patients whose treatment regimen includes protease inhibitors.

    Design 

    Decision analysis with Markov modelling of the natural history of advanced HIV disease.

    Five strategies were evaluated : no prophylaxis, azithromycin, rifabutin, clarithromycin and a combination of azithromycin plus rifabutin.

    Main outcome measures 

    Survival, quality of life, quality-adjusted survival, health care costs and marginal cost-effectiveness ratios.

    Results 

    Compared with no prophylaxis, rifabutin increased life expectancy from 78 to 80 months, increased quality-adjusted life expectancy from 50 to 52 quality-adjusted months and increased health care costs from $233 000 to $239 800.

    Ignoring time discounting and quality of life, the cost-effectiveness of rifabutin relative to no prophylaxis was $44 300 per life year.

    Adjusting for time discounting and quality of life, the cost-effectiveness of rifabutin relative to no prophylaxis was $41 500 per quality-adjusted life year (QALY).

    In comparison with rifabutin, azithromycin was associated with increased survival, increased costs and an incremental cost-effectiveness ratio of $54 300 per QALY. (...)

    Mots-clés Pascal : SIDA, Virose, Infection, Infection opportuniste, Complication, Mycobactériose, Bactériose, Mycobacterium avium, Mycobacteriaceae, Mycobacteriales, Actinomycetes, Bactérie, Complexe espèces, Rifabutine, Chimioprophylaxie, Antibactérien, Azithromycine, Clarithromycine, Analyse coût efficacité, Survie, Qualité vie, Coût, Pronostic, Homme, Macrolide, Immunopathologie, Immunodéficit, Economie santé

    Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Opportunistic infection, Complication, Mycobacterial infection, Bacteriosis, Mycobacterium avium, Mycobacteriaceae, Mycobacteriales, Actinomycetes, Bacteria, Species complex, Rifabutin, Chemoprophylaxis, Antibacterial agent, Azithromycin, Clarithromycin, Cost efficiency analysis, Survival, Quality of life, Costs, Prognosis, Human, Macrolide, Immunopathology, Immune deficiency, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0420418

    Code Inist : 002B02S05. Création : 25/01/1999.